Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
BICO Group AB specializes in advanced bioprinting and biofabrication technologies, primarily serving the healthcare sector with a focus on personalized medicine and regenerative therapies. Its competitive position is bolstered by proprietary technologies in 3D bioprinting and a strong presence in Europe and North America, which allows for innovative product offerings in tissue engineering and drug development.
BICO generates revenue through the sale of bioprinting systems and consumables, alongside contract research services for pharmaceutical companies. Its competitive advantages include proprietary bioprinting technology that allows for high precision and customization, catering to the growing demand for personalized medicine.
Regulatory approvals for new bioprinting technologies
Partnerships with pharmaceutical companies for drug development
Market adoption rates of bioprinting in regenerative medicine
Changes in reimbursement policies for advanced medical devices
Technological disruption from emerging bioprinting competitors
Regulatory changes impacting the approval process for medical devices
Increased competition from established medical device companies entering the bioprinting space
Potential for new entrants with innovative technologies
Negative net margins leading to potential liquidity issues if cash flow does not improve
Dependence on external funding for R&D initiatives
moderate - BICO's business is somewhat tied to the healthcare spending cycle, which can be influenced by GDP growth and consumer spending on medical innovations.
Interest rates affect BICO's financing costs for R&D and capital expenditures. Higher rates could dampen investment in new technologies and reduce demand for its products.
minimal - BICO's current debt levels are manageable, and it does not heavily rely on credit for operations.
growth - Investors are likely attracted to BICO for its potential in the rapidly evolving bioprinting market.
high - The stock has shown significant volatility, reflected in its recent performance metrics.